Immuneering Corp [IMRX] stock prices are up 4729250% to $888100.0 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IMRX shares have gain 30.61% over the last week, with a monthly amount glided 63.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immuneering Corp [NASDAQ: IMRX] stock has seen the most recent analyst activity on December 13, 2024, when Morgan Stanley downgraded its rating to a Underweight. Previously, Needham reaffirmed its Buy rating on March 15, 2024, and dropped its price target to $15. On March 15, 2024, downgrade downgraded it’s rating to Market Perform. Jefferies downgraded its rating to a Hold and decreased its price target to $3 on March 15, 2024. Needham initiated its recommendation with a Buy and recommended $20 as its price target on December 01, 2023. In a note dated April 19, 2023, Morgan Stanley upgraded an Equal-Weight rating on this stock and boosted its target price from $5 to $14.
The stock price of Immuneering Corp [IMRX] has been fluctuating between $1.00 and $3.83 over the past year. Currently, Wall Street analysts expect the stock to reach $17.5 within the next 12 months. Immuneering Corp [NASDAQ: IMRX] shares were valued at $888100.0 at the most recent close of the market. An investor can expect a potential drop of -100.0% based on the average IMRX price forecast.
Analyzing the IMRX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.22, Equity is -1.19 and Total Capital is -1.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Immuneering Corp [NASDAQ:IMRX]’s Current Ratio is 7.48. Further, the Quick Ratio stands at 7.48, while the Cash Ratio is 7.02.
Transactions by insiders
Recent insider trading involved Zeskind Benjamin J., PRESIDENT AND CEO, that happened on Jun 18 ’25 when 21000.0 shares were purchased. Director, Schall Thomas J. completed a deal on Jun 17 ’25 to buy 40485.0 shares.
